The CCK-8 assay (Fig. 2A, Additional file 2: Fig S2A) revealed that the survival rate of B-ALL cells treated with recombinant netrin-1 was higher than that of the control group (no recombinant netrin-1 treatment). The gene discussed is NTN1; the disease is acute lymphoblastic leukemia.